BASEL LIFE 2019

9–12 September 2019

Congress Center Basel
Switzerland

Cellular allergy

Date

Thursday, 12 September 2019

Chairs

Michael A. Gerspach (BÜHLMANN Laboratories, Switzerland)
Christian B. Gerhold (BÜHLMANN Laboratories, Switzerland)

Abstracts

 

Allergic reactions are common phenomena during which the immune system overreacts to typically harmless substances from the environment. These hypersensitivities are mostly mediated by IgE antibodies that recognize the allergen and then trigger a cellular reaction that may lead to a severe and possibly lethal anaphylactic shock. This innovation forum at BASEL LIFE 2019 on cellular allergy shall be a platform to present cutting-edge research on cellular allergy and its implication in immunotherapy together with novel in vitro approaches in allergy diagnostics and therapy monitoring. The transition from in vivo oral food challenges or skin-prick tests to in vitro assays based on basophil activation as well as expected FDA clearances of oral immunotherapies are current game changers in allergy diagnostics and treatment. Additionally, the role of IgE directed immunotherapy (Omalizumab, Xolair®) as stand-alone and synergistic treatment will be discussed. Concomitant monitoring of therapy success with ex vivo challenges is expected to alleviate the burden on allergy patients significantly.

Deciphering the complex interplay of the allergen and immune cell signalling and hence the understanding of allergy on a cellular and molecular level will shape allergy treatment and diagnosis in the near future. A specific allergic reaction can be mimicked in a test tube by provoking patient-derived basophil cells ex vivo with the appropriate allergens that trigger a PI3 like kinase signalling cascade in these blood cells. This allows its application beyond allergy monitoring as for instance various Bruton’s kinase inhibitors, such as Ibrutinib (IMBRUVICA®), which are used to treat various lymphoma and leukemia, could also be applied for therapy of allergy. Therefore, the innovation forum also aims to present novel discoveries in cellular allergy signalling and their exploitation beyond allergy treatment.

 

Forum Part 1: Novel strategies for allergy treatment and monitoring Chair: Dr. Michael A. Gerspach (BÜHLMANN Laboratories AG)

Forum Part 2: Cellular signaling in allergy and beyond Chair: Dr. Christian B. Gerhold (BÜHLMANN Laboratories AG)

Thursday, 12 September 2019

9.00 – 15.30

Part 1: Novel strategies for allergy treatment and monitoring

09.00
Introduction

09.15
Cellular Allergy and novel therapy approaches
PD. Dr. Alexander Eggel (University Hospital, Bern Switzerland)

09.45
Recent breakthroughs in immunotherapy of allergy
Dr. Wayne Shreffler (Massachusetts General Hospital, Boston USA)

10.15
Break

10.45
Molecular and functional differences of anti-IgE antibodies ligelizumab and omalizumab
Dr. Christoph Heusser (NIBR Basel, Switzerland)

11.15
Novel approaches for allergy diagnosis and immunotherapy monitoring
Dr. Alexandra Santos (King´s College, London, United Kingdom)

11.45
Break

Part 2: Cellular signalling in allergy and beyond

12.00
How allergens become allergic – the role of the alarmin cytokine IL-33 in allergen sensing
Prof. Dr. Jean-Phillipe Girard ( Institut de Pharmacologie et de Biologie Structurale (IPBS), Toulouse, France)

12.30
Orchestrating signalling in allergic inflammation
Prof. Dr. Matthias Wymann (University of Basel, Basel, Switzerland)

13.00
Lunch Break & Industry Symposia


14.30
PI3K signalling in allergic asthma
Dr. Augustin Amour (GSK, Stevenage, United Kingdom)              

15.00
Use of PI3K inhibitors to prevent cellular and clinical allergic respones

Prof. Dr. Bruce Bochner (Northwestern Medicine, Chicago, USA)

Room Rio

Supporter(s)